$IMNN

Imunon Inc. (NASDAQ:IMNN) updated its pivotal Phase 3 OVATION 3 trial of IMNN-001 in newly diagnosed advanced ovarian cancer. The company said site activation and enrollment are ahead of forecasts, with full enrollment expected by Q2 2029. It reported no cytokine release syndrome or serious immune-related adverse events and noted two interim analyses that could support an early BLA. Shares rose 1.95% to $1.57 premarket.

IMUNON (Nasdaq: IMNN) provided an update on its pivotal Phase 3 OVATION 3 trial of IMNN-001 in newly diagnosed advanced ovarian cancer. The company said enrollment is ahead of plan, with a study rate of about 0.5 patients per site per month versus 0.3 planned, and it now expects completion in Q2 2029. It reported no cytokine release syndrome and comparable safety versus control.

Imunon said its IMNN-001 plus standard chemotherapy and bevacizumab lowered surgical MRD-positive rates in a multi-site advanced ovarian cancer study, 44% vs 67%, and improved ctDNA clearance, 87.5% vs 62.5%. The company also cited prior OVATION 2 results with median OS up 14.7 months. Imunon shares rose to $1.91 premarket.

Imunon, Inc. (IMNN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0000749647 0000749647 2026-06-29 2026-06-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report

Imunon, Inc. (IMNN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ex10-1.htm EX-10.1 EXHIBIT 10.1 IMUNON, INC. THE 2018 STOCK INCENTIVE PLAN AS AMENDED AS OF JUNE 16, 2026 I. INTRODUCTION 1.1 Purposes . The purposes of the IMUNON, INC. 2018 Stock Incentive Plan (this “ Plan ”) are (i) to align the interests of the Company’s stockholde

Imunon Inc. (NASDAQ:IMNN) said it secured a $10 million financing package to advance its Phase 3 OVATION 3 ovarian cancer trial of IMNN-001. The company will receive $2.5 million via 250 non-redeemable, non-convertible preferred shares and about $7.72 million through two secured promissory notes at 8% and 5% interest, maturing in 18 months. Imunon cited updated Phase 2 survival data.

IMUNON (NASDAQ: IMNN) will host a conference call on May 12, 2026, to discuss its first-quarter 2026 financial results and provide an update on the Phase 3 clinical development of its lead candidate, IMNN-001, for advanced ovarian cancer. The company has previously utilized such calls to highlight progress on IMNN-001, with past announcements generating mixed stock price reactions. This event is expected to clarify trial progress, financing, and any changes from previous updates.

IMUNON, Inc. (Nasdaq: IMNN) reported its financial results for the year ended December 31, 2025, detailing a net loss of $14.5 million. The company highlighted significant progress in its pivotal Phase 3 OVATION 3 Study for IMNN-001 in advanced ovarian cancer, with final Phase 2 data showing continued improvements in median overall survival. IMUNON also discussed its PlaCCine DNA vaccine technology and strategic efforts to reduce operating expenses while advancing its lead candidate.

Imunon (IMNN) has expanded its at-the-market (ATM) equity offering capacity to $17 million by registering an additional $7 million of common stock with H.C. Wainwright & Co. This move indicates the company's ongoing reliance on public equity markets for funding, which could lead to future shareholder dilution. While an analyst has a Buy rating on IMNN with a $25.00 price target, TipRanks' AI Analyst, Spark, rates it Neutral due to weak financial performance and technical downtrends, despite positive earnings call updates.

Image source: The Motley Fool.Thursday, November 13, 2025 at 11:00 a.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...